CORE--TISSUE CULTURE AND VECTOR
核心——组织培养和载体
基本信息
- 批准号:6424496
- 负责人:
- 金额:$ 5.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1976
- 资助国家:美国
- 起止时间:1976-03-01 至 2006-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The Cell Culture and Virus Vector Core Laboratory provides essential cell culture tools and the expertise our investigators need to make these tools work for them in their cancer-focused projects. This Core Laboratory has expanded its services since the last grant cycle and has developed a state-of-the-art virus production facility for preclinical trials in animals targeted for eventual cancer therapeutic trials. We will work closely with the produced Good Manufacturing Practice (GMP) facility that is planned for completion in 2000 for production of virus vectors for use in human clinical trials. This added expertise has increased the Core's ability to facilitate translational research and scientific excellence in alignment with the overall goals of the laboratory. We currently provide a wide array of essential services to Cancer Center members including: providing large quantities of virus vectors, tissue culture cells, media and reagents; maintaining a repository of transformed secondary and continuous cell strains and cell lines; providing assistance to investigators in DNA cloning, molecular characterizing of cloned recombinant DNA, amplification and purification of recombinant plasmid DNA; making available specialized equipment and a centralized biohazard containment facility for use by investigators; aiding new investigators in starting their research programs; and cryopreservation of non-transformed and transformed tissue culture cells. We have also developed new services which include production of vaccinia virus and simian virus 5 vectors; methods for growth and maintenance of amphotropic recombinant retroviruses in murine culture cells; expansion of the cell repository to include specialized transformed cell lines requested; and establishment of methods for expansion of transformed cells for large scale extraction and characterization of proteins and lipids. Current usage of the Cull Culture and Virus Vector Core Laboratory by Cancer Center approved projects has been 75% of overall use. over the past two years, due to the substantial reduction in the size of the Cancer Center Support Grant, the Analytical Chemistry Core Laboratory received 1% of its funding from the CCSG. In the current proposal we are requesting $69,723 or 53% of the total annual budget of the laboratory ($131,230).
细胞培养和病毒载体核心实验室提供必要的细胞培养工具和我们的研究人员需要的专业知识,使这些工具在他们的癌症为重点的项目工作。自上一个资助周期以来,该核心实验室扩大了其服务,并开发了最先进的病毒生产设施,用于最终癌症治疗试验的动物临床前试验。我们将与已建成的良好生产规范(GMP)设施密切合作,该设施计划于2000年完工,用于生产用于人体临床试验的病毒载体。这增加了专业知识,提高了核心的能力,以促进转化研究和科学卓越与实验室的总体目标相一致。我们目前为癌症中心会员提供广泛的基本服务,包括:提供大量病毒载体、组织培养细胞、培养基和试剂;维护转化的二级和连续细胞株和细胞系的储存库;为研究人员提供DNA克隆、克隆重组DNA的分子表征、重组质粒DNA的扩增和纯化方面的帮助;提供专门的设备和集中的生物危害控制设施供研究人员使用;帮助新的研究人员开始他们的研究计划;冷冻保存未转化和转化的组织培养细胞。我们还开发了新的服务,包括生产牛痘病毒和猿猴病毒5载体;在小鼠培养细胞中生长和维持嗜中性重组逆转录病毒的方法;扩大细胞库,以包括所需的专门转化细胞系;以及建立用于大规模提取和表征蛋白质和脂质的转化细胞扩增方法。目前,癌症中心批准的项目对Cull Culture and Virus Vector Core Laboratory的使用率已达到总使用率的75%。在过去的两年里,由于癌症中心支持补助金的规模大幅减少,分析化学核心实验室从CCSG获得了1%的资助。在目前的提案中,我们要求69,723美元,即实验室年度预算总额(131,230美元)的53%。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LOUIS S KUCERA其他文献
LOUIS S KUCERA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LOUIS S KUCERA', 18)}}的其他基金
INFLUENCE OF HUMAN IMMUNODEFICIENCY VIRUS ON NATURAL SUPPRESSOR ACTIVITY
人类免疫缺陷病毒对自然抑制活性的影响
- 批准号:
3930181 - 财政年份:
- 资助金额:
$ 5.34万 - 项目类别:
相似海外基金
Study of the parainfluenza virus interferon antagonism as a basis for attenuated recombinant virus vaccines
副流感病毒干扰素拮抗作用作为减毒重组病毒疫苗基础的研究
- 批准号:
19K08928 - 财政年份:2019
- 资助金额:
$ 5.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of new mumps vaccine induced by genomic recombinant virus vector system
基因组重组病毒载体系统诱导的新型腮腺炎疫苗的研制
- 批准号:
16K10040 - 财政年份:2016
- 资助金额:
$ 5.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A recombinant virus approach for gamma herpesvirus oncogenesis
用于伽马疱疹病毒肿瘤发生的重组病毒方法
- 批准号:
8638543 - 财政年份:2013
- 资助金额:
$ 5.34万 - 项目类别:
Live attenuated nairovirus vaccines: targeted mutations in a recombinant virus
内罗病毒减毒活疫苗:重组病毒的靶向突变
- 批准号:
BB/F006764/2 - 财政年份:2011
- 资助金额:
$ 5.34万 - 项目类别:
Research Grant
Establishment of a simple, easy and useful new recombinant virus manufacture system using a homologous recombination phenomenon
利用同源重组现象建立简单、容易、有用的新型重组病毒生产系统
- 批准号:
23658240 - 财政年份:2011
- 资助金额:
$ 5.34万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Analysis of virus replication mechanism using minigenome or recombinant virus system
利用小基因组或重组病毒系统分析病毒复制机制
- 批准号:
23590539 - 财政年份:2011
- 资助金额:
$ 5.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Live attenuated nairovirus vaccines: targeted mutations in a recombinant virus
内罗病毒减毒活疫苗:重组病毒的靶向突变
- 批准号:
BB/F00740X/1 - 财政年份:2009
- 资助金额:
$ 5.34万 - 项目类别:
Research Grant














{{item.name}}会员




